GLP-1

News

Novo Nordisk follows Lilly into DTC obesity drug market

Novo Nordisk has launched direct-to-consumer sales of its obesity drug Wegovy for uninsured or under-insured people at $499 per month.

News

Small study finds GLP-1 drug can curb excess alcohol use

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder.

Digital

Looking beyond the scale: Why measures of physical activity ...

GLP-1 receptor agonists like Ozempic and Wegovy are dramatically changing how healthcare professionals approach the treatment of obesity in patients.

R&D

Clinical trends for 2025: A year of change

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and development, particularly in clinical trials.

R&D

Pharma 2025: AI, GLP-1 competition, and the future of clinic...

I’ve worked in clinical trials for twenty years. For most of that time, the core processes and challenges have been fairly consistent, with incremental improvements along the way.

News